Prime Medicine
PRME · NASDAQ
$3.92+$0.09 (+2.35%)TodayMarket closed ·
Prev close $3.83
Who owns PRME
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 59.0% of PRME’s shares.
- Liu (David R)11.2%
- ARCH Venture Partners10.2%
- Alphabet, Inc.9.2%
- Bristol Myers Squibb6.1%
- Next 6 largest institutions22.3%
- All other shareholders41.0%
| Holder | Shares | % of shares |
|---|---|---|
| Liu (David R) | 20.24M | 11.21% |
| ARCH Venture Partners | 18.49M | 10.24% |
| Alphabet, Inc. | 16.56M | 9.17% |
| Bristol Myers Squibb | 11.01M | 6.09% |
| BlackRock Institutional Trust Company, N.A. | 8.44M | 4.67% |
| ARK Investment Management LLC | 8.35M | 4.62% |
| State Street Investment Management (US) | 7.58M | 4.19% |
| Newpath Partners LP | 6.11M | 3.38% |
| T. Rowe Price Investment Management, Inc. | 5.24M | 2.90% |
| Vanguard Capital Management, LLC | 4.52M | 2.50% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| ARK Genomic Revolution ETF | 7.94M | 4.40% |
| State Street SPDR S&P Biotech ETF | 5.52M | 3.05% |
| Vanguard Total Stock Market Index Fund | 3.12M | 1.73% |
| iShares Russell 2000 ETF | 2.50M | 1.38% |
| ARK Venture Fund | 2.48M | 1.37% |
Insider trades
Form 4 filings by officers, directors and large holders
Insiders made no open-market buys or sales of PRME in the last 6 months.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Chung Wendy | Award | 75.00K | — |
| Cahill Thomas | Award | 75.00K | — |
| Kelly Michael Aaron | Award | 75.00K | — |
| Marrazzo Jeffrey D | Award | 75.00K | — |
| Schenkein David P | Award | 75.00K | — |
| Foster-Cheek Kaye I | Award | 75.00K | — |
| NELSEN ROBERT | Award | 75.00K | — |
Short interest
Settled Sep 30, 2026
- Shares short
- 32.12M
- Days to cover
- 8.45
- % of shares outstanding
- 17.78%
- Average daily volume
- 3.80M
- Change since last report
- −0.0%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.